ABSTRACT
Sequence-based genetic testing currently identifies causative genetic variants in ∼50% of individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA methylation are implicated in various neurodevelopmental disorders but remain unstudied in DEEs. Rare epigenetic variations (“epivariants”) can drive disease by modulating gene expression at single loci, whereas genome-wide DNA methylation changes can result in distinct “episignature” biomarkers for monogenic disorders in a growing number of rare diseases. Here, we interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral blood samples from 516 individuals with genetically unsolved DEEs who had previously undergone extensive genetic testing. We identified rare differentially methylated regions (DMRs) and explanatory episignatures to discover causative and candidate genetic etiologies in 10 individuals. We then used long-read sequencing to identify DNA variants underlying rare DMRs, including one balanced translocation, three CG-rich repeat expansions, and two copy number variants. We also identify pathogenic sequence variants associated with episignatures; some had been missed by previous exome sequencing. Although most DEE genes lack known episignatures, the increase in diagnostic yield for DNA methylation analysis in DEEs is comparable to the added yield of genome sequencing. Finally, we refine an episignature for CHD2 using an 850K methylation array which was further refined at higher CpG resolution using bisulfite sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate genetic causes as ∼2% (10/516) for unsolved DEE cases.
Competing Interest Statement
B.S. is a shareholder in EpiSign Inc, a company involved in commercialization of EpiSignTM software. D.E.M is on a scientific advisory board at ONT and has received travel support from ONT to speak on their behalf. D.E.M is engaged in a research agreement with ONT. D.E.M holds stock options in MyOme. I.E.S. has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, Xenon Pharmaceuticals, Cerecin; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, Stoke Therapeutics and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, Encoded Therapeutics Stoke Therapeutics and Eisai; has served as an investigator for Anavex Life Sciences, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix and Zynerba; has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics and Biohaven Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited. I.E.S. may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies; has a patent molecular diagnostic/theragnostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). L.G.S. receives funding from the Health Research Council of New Zealand and Cure Kids New Zealand, is a consultant for the Epilepsy Consortium, and has received travel grants from Seqirus and Nutricia. L.G.S. has received research grants and consultancy fees from Zynerba Pharmaceuticals and has served on and Takeda and Eisai Pharmaceuticals scientific advisory panels. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratories.
Funding Statement
We thank all the individuals and their families for participating in this research. Major funding for this project was provided by a grant (#631106) from Citizens United for Research in Epilepsy (CURE). A subset of DNA methylation arrays was provided by the University of Washington Center for Rare Disease Research (UW-CRDR), formerly known as the Center for Mendelian Genomics (CMG), with support from NHGRI grants U01 HG011744, UM1 HG006493 and U24 HG011746 and with enthusiastic support from the late Debbie Nickerson. We gratefully acknowledge support from the Health Research Council of New Zealand, Cure Kids New Zealand, and the Estate of Ernest Hyam Davis and the Tedd and Mollie Carr Endowment Trust. We acknowledge the Epi25 Consortium, which provided exome sequence data for review for a subset of individuals. C.W.L. has been funded through the American Epilepsy Society (AES) predoctoral fellowship and the St. Jude Graduate School of Biomedical Sciences. We would also like to acknowledge the inaugural St. Jude Biohackathon 2022 for coordinating the event that led to a team comprised of C.W.L., P.K., M.D., and W.R., who assembled the MethylMiner pipeline described here. D.E.M. is supported by NIH grant DP5OD033357. Research reported in this manuscript by M.W.H., S.K., H.D., K.C.W., J.A.R., and H.T.C., was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Numbers U01HG007709 and U01HG007942. K.L.P. has been funded through the GRIN2B foundation and CURE. We gratefully acknowledge support provided by the Australian Epilepsy Research Foundation grant, Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence Grant (GNT2006841), and NHMRC Synergy Grant (GNT2010562). I.E.S. is also supported by a NHMRC Senior Investigator Fellowship (GNT1172897).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of St. Jude Childrens Research Hospital (SJCRH) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and Code Availability
Methylation array data for individuals with unsolved DEEs and those with pathogenic variants in CHD2 who have given consent for data sharing will be made available through dbGaP. Additional data requests can be directed to H.C.M. The methylation array analysis pipeline used in part of this study for epivariant detection can be accessed on GitHub: https://github.com/stjude-biohackathon/MethylMiner. EpiSignTM is proprietary commercial software and is not publicly available.
